MedTrace Logo

Application of Guidelines for Medico-professional Supervision of Workers Exposed to Carcinogenic Action of Wood Dust: CERBois Cohort

NCT02884232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2016-08-30

No results posted yet for this study

Summary

The purpose is to evaluate feasibility of medical supervision of professionally active asymptomatic wood workers with questionnaires and nasofibroscopy.

Secondary purposes are:

* Feasibility evaluation of identification of former and actual professional expositions to wood dust and to various naso-sinusal carcinogenics in case of co-expositions (formaldehyde, chrome, nickel, leather)
* Description of abnormal symptoms identified by occupational doctor and needing an otorhinolaryngology test
* Description of results and examinations induced by nasofibroscopy in symptomatic or asymptomatic individuals: counting of naso-sinusal adenocarcinoma cases
* Evaluation of participation of workers retiring in 2 years after inclusion to medical supervision program
* Evaluation of information flow among different players
* Assessment of costs induced by this targeted screening: direct medical costs (screened pathologies, induced additional examinations…) and indirect costs for company (duration of worker absence for transfer, medical and additional examinations).

Conditions

  • Exposition to Wood Dust

Interventions

PROCEDURE

Nasofibroscopy

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Christophe PARIS, Pr · Centre de Consultations de Pathologies Professionnelles - Hôpitaux de Brabois - CHU de Nancy - France

Eligibility

Min Age
44 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02884232 on ClinicalTrials.gov